<DOC>
	<DOC>NCT02633020</DOC>
	<brief_summary>Protocol CELIM-RCD-002 is designed to be a Phase 2a randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AMG 714 for the treatment of adult patients with Type II Refractory Celiac Disease (RCD-II), an in situ small bowel T cell lymphoma.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Confirmed diagnosis of refractory celiac disease Type 2 (RCDII) Greater than 20% aberrant intraepithelial lymphocytes (IEL) as assessed by flow cytometry On a glutenfree diet for at least 6 months Avoid pregnancy EnteropathyAssociated T cell Lymphoma (EATL) Infections Immune suppression Clinically significant comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>